MyFinsight

HomeBlogAboutContact

MyFinsight

Making company financials insightful for everyone

Quick Links

  • About
  • Blog
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

|||

For the year ending 2025-12-31.

Income Overview

Net Income
-$7,866,617
EPS
-$0.39
Unit: Dollar

Income Statement
2025-12-31
Selling, general and administrative expenses
2,887,358
Research and development expenses
121,085
Stock-based compensation
4,142,816
Total operating expenses
7,151,259
Loss from operations
-7,151,259
Interest income
167,103
Interest expense
415,890
Operating sublease income
134,196
Loss on foreign exchange changes
-77,546
Loss on investment in equity securities
-192,759
Loss on impairment of equity investment
-803,008
Other (loss) income, net
-13,642
Total other (expenses)
-1,201,546
Loss before provision for income tax
-8,352,805
Provision for income tax expense (benefit)
24,154
Net loss
-8,376,959
Net loss attributable to noncontrolling interests
-468,405
Net loss attributed to abvc and subsidiaries
-7,908,554
Foreign currency translation adjustment
41,937
Comprehensive loss
-7,866,617
Basic EPS
-0.39
Diluted EPS
-0.39
Basic Average Shares
20,108,944
Diluted Average Shares
20,108,944
Unit: Dollar.

Time Plot

Show the time plot by selecting a row from the table.

Income Statement

DownloadDownload image
Comprehensive loss-$7,866,617 Foreign currencytranslation adjustment$41,937 Net loss attributedto abvc and...-$7,908,554 Net lossattributable to...-$468,405 Net loss-$8,376,959 Loss beforeprovision for income tax-$8,352,805 Provision for income taxexpense (benefit)$24,154 Loss from operations-$7,151,259 Total other(expenses)-$1,201,546 Interest income$167,103 Operating sublease income$134,196 Total operatingexpenses$7,151,259 Loss on impairment ofequity investment-$803,008 Interest expense$415,890 Loss on investment inequity securities-$192,759 Loss on foreignexchange changes-$77,546 Other (loss) income,net-$13,642 Stock-based compensation$4,142,816 Selling, general andadministrative expenses$2,887,358 Research and developmentexpenses$121,085

ABVC BIOPHARMA, INC. (ABVC)

ABVC BIOPHARMA, INC. (ABVC)